Tilray stock price popped by nearly 30% on Tuesday as Donald Trump prepared to sign an executive order that would reschedule cannabis into a lower drug classification. It jumped to a high of $14.40, u... ...

来源：环球市场播报 美股周一早盘，大麻类股票Tilray股价下跌5.9%，部分回吐了上周五高达44%的涨幅。上周该股因一则 消息大涨；该消息称，美国总统将特朗普指示联邦机构将大麻从目前的Ⅰ类管制物质重新归类为管制较 宽松的Ⅲ类。 ...

Core Viewpoint - The article discusses the anticipated executive order by President Trump to reclassify cannabis from Schedule I to Schedule III, which is expected to significantly relax regulations and encourage investment in the cannabis industry [1][6][7]. Group 1: Regulatory Changes - The expected executive order will allow cannabis businesses to benefit from different tax rules and facilitate banking services for the industry [3][8]. - The reclassification is seen as a positive development for the cannabis sector, with expectations that the Drug Enforcement Administration (DEA) will establish proposed rules for reclassification by next summer [8]. Group 2: Market Reaction - Following the news, cannabis stocks experienced substantial gains, with Tilray Brands rising by 44% and Canopy Growth soaring by 53% during the trading session [4]. - The Amplify Seymour Cannabis ETF surged over 54%, marking its best single-day performance in history [4]. Group 3: Industry Sentiment - The CEO of Tilray expressed increased optimism about the cannabis market, noting that the stock has struggled since the pandemic despite a previous peak of over $2140 in September 2018 [9].

Core Viewpoint - Cannabis stocks experienced a significant surge, with Tilray Brands rising over 32%, Canopy Growth increasing over 23%, SNDL up over 19%, Aurora Cannabis rising over 11%, and Cronos Group gaining over 5% due to reports that President Donald Trump is considering reclassifying cannabis to a lower risk category [1] Group 1 - Tilray Brands (TLRY.US) saw an increase of over 32% [1] - Canopy Growth (CGC.US) rose by more than 23% [1] - SNDL (SNDL.US) increased by over 19% [1] - Aurora Cannabis (ACB.US) experienced a rise of over 11% [1] - Cronos Group (CRON.US) gained over 5% [1] Group 2 - Reports indicate that President Trump is expected to push for the reclassification of cannabis as a "lower risk drug" [1] - Trump is considering moving cannabis from Schedule I, which indicates no medical use and high abuse potential, to Schedule III, which includes substances with lower dependency and addiction potential [1]

智通财经APP获悉，周五，大麻股集体狂飙，Tilray Brands(TLRY.US)大涨超32%，canopy growth(CGC.US)涨超23%，SNDL(SNDL.US)涨超19%，极光大麻(ACB.US)涨超11%，cronos group(CRON.US)涨超5%。消息面上，多家美国当地媒体报道称，美国总统唐纳德.特朗普预计将推动把 大麻重新归类为"危害性较低的药物"。根据媒体报道，特朗普正在考虑将大麻从"附表I"(Schedule I) ——该类别表示无医疗用途且具有高滥用潜力——大幅度调整至"附表III"——这是一类依赖性与成瘾性 潜力较低的物质类别。 ...

大麻股大涨，Tilray Brands涨38.8%，Canopy Growth涨23.0%，极光大麻涨18.5%，SNDL涨20.2%，美国 政府将大幅放宽对大麻的管制。博通跌6.3%，730亿美元AI订单令投资者失望。Lululemon涨9.6%，Q3 业绩超预期，新增10亿美元股票回购。瑞银涨1.7%，瑞士议员就资本监管规则提出折衷方案。 来源：滚动播报 ...

智通财经APP获悉，多家美国当地媒体报道称，美国总统唐纳德·特朗普预计将推动把大麻重新归类 为"危害性较低的药物"，这一最新的市场动态无疑直接推动美国大麻类生产商股票周五在美股盘前交易 中大幅上涨。涨幅居前的包括：Tilray Brands(TLRY.US)盘前大涨超30%，Canopy Growth(CGC.US)涨 23%，Aurora Cannabis(ACB.US)涨20%，SNDL(SNDL.US)涨14%，Cronos Group(CRON.US)涨12%。 根据媒体报道，特朗普正在考虑将大麻从"附表I"(Schedule I)——该类别表示无医疗用途且具有高滥用 潜力——大幅度调整至"附表III"——这是一类依赖性与成瘾性潜力较低的物质类别。 据报道，特朗普当地时间周四早些时候与美国众议院议长迈克·约翰逊、特朗普亲自提名的卫生与公众 服务部(HHS)部长小罗伯特·F·肯尼迪、医疗保险和医疗补助服务中心(CMS)署长梅赫梅特·奥兹，以及数 位大麻行业高管通话，讨论该事项。 不过报道称，联系到的一名白宫高级官员表示，特朗普本人尚未给出最终的行政决定。 附表III药物具有已被普遍接受的医疗用途，但仍存 ...

The company opened the doors of a new dispensary, while lawmakers in Congress submitted a new pot reform resolution.Marijuana company Curaleaf (CURLF +9.02%) is expanding its presence in a potentially massive market, a move that resonated with investors on Thursday. That, plus a new weed reform resolution filed in the U.S. Congress, helped push the multi-state operator's (MSO) stock price up by 9% that trading session. Making hay while the sun shinesAfter market close Wednesday, Curaleaf announced it had op ...

Core Viewpoint - The cannabis industry, particularly Tilray Brands, is characterized by significant volatility and risks, with the stock experiencing a dramatic decline despite earlier gains [1][2]. Company Performance - Tilray's stock has decreased over 91% in the past five years and is currently down 66% from its 52-week high [2]. - The stock was once up as much as 58% earlier this year but has since fallen back to a decline of over 40% [4][5]. - The company's market capitalization stands at $8 billion, with a current stock price of $7.06 [4]. Market Expectations - There were high hopes for marijuana rescheduling in the U.S., which would have eased research and tax burdens, but these hopes have not materialized [2][3]. - Despite being a leading cannabis producer in Canada, Tilray has not made significant progress towards its ambitious revenue target of $4 billion by 2024, with trailing revenue at only $831 million [5][6]. Financial Health - The company has been reducing its cash burn but continues to face operating losses and lacks organic growth [7][8]. - Management's forecasts for revenue growth in international markets remain unfulfilled, leading to investor skepticism [6][7]. Speculative Nature - Tilray is considered a highly speculative stock, with potential for sudden surges in value based on positive industry news, but such rallies are often short-lived [9][10]. - The overall sentiment suggests that investors should maintain caution due to the stock's volatility and unpredictability [10].

Group 1 - The article emphasizes that Canada is an attractive option for Chinese companies seeking overseas financing, especially given the increasing competition in the US capital markets [2] - It outlines ten core questions regarding the Canadian capital market to provide clear guidance for companies looking to go public [2] Group 2 - The main stock exchanges in Canada include the Toronto Stock Exchange (TSX), which has a main board for larger, mature companies and a venture board (TSXV) for smaller, growth-oriented firms [4] - The Canadian Securities Exchange (CSE) also offers listing services for small and micro enterprises, creating a multi-tiered capital market system [4] Group 3 - Advantages of financing in Canada include a stable financial services system, access to North American capital integration, and increased fundraising opportunities in the US [5] - The TSX offers two main listing methods: Initial Public Offerings (IPOs) and Capital Pool Company (CPC) listings [6] Group 4 - The CPC model is suitable for shell companies that only hold cash and seek to go public quickly while looking for acquisition targets [7] - Domestic companies can utilize various fundraising methods after listing in Canada, including IPOs, stock issuance, bond issuance, and stock pledges [8] Group 5 - Compared to the US capital markets, the time and cost of listing in Canada are more advantageous, with Canadian listings taking about six months and costing approximately 50% of Nasdaq fees [9] Group 6 - Companies listed in Canada can transfer to the US market using the Multi-Jurisdictional Disclosure System (MJDS), which allows for a quick transfer process within 90 days [10] Group 7 - Industries such as mining and energy have significant advantages in the Canadian capital market, with the TSX being a major global mining capital market [11] - Other sectors like fintech, environmental technology, and biomedicine can achieve high valuations, and even industries like cannabis are permitted to list [11] Group 8 - Domestic mining companies need to prepare various qualifications and financial requirements before listing on the TSX, and it is advisable to collaborate with experienced firms like Huayi Capital for guidance [12] Group 9 - Huayi Capital offers tailored listing advisory services for companies looking to enter the Canadian market, leveraging local resources and expertise to create efficient and cost-effective listing strategies [13]